Statins benefit low-risk patients

MedPage Today reports, “A large meta-analysis suggests that statins provide substantial benefit for primary prevention, prompting researchers to question current guidelines.”

In patients “without a history of cardiovascular disease, statins reduced the risk of vascular and all-cause mortality by 15% and 9%, respectively, for every 1 mmol/L reduction in low-density lipoprotein (LDL) cholesterol, according to Borislava Mihaylova, MSc DPhil, and colleagues on the Cholesterol Treatment Trialists’ (CTT) Collaborators writing team.”

Altogether, “in the five baseline risk groups, there was a 21% reduction in the relative risk of major vascular events and all-cause death, irrespective of age, baseline LDL, or previous cardiovascular disease for every 1 mmol/L reduction in LDL cholesterol (P<0.001), they reported online in The Lancet.”

HeartWire reports, “There was no evidence that reduction of LDL cholesterol with a statin increased cancer incidence (RR per 1.0-mmol/L LDL-cholesterol reduction 1.00, 95% CI 0.96-1.04), cancer mortality (RR 0.99, 95% CI 0.93-1.06), or other nonvascular mortality.”

This entry was posted in General Health. Bookmark the permalink.